Source: International Congress 2017 – Lung fibrosis: basic science
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Lipson (San Francisco, United States of America). Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model. 908

Member's Comments

No comment yet.

Related content which might interest you: Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Effect of Nintedanib in a rat model of bleomycin-induced lung fibrosis: a transcriptome analysis Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021 Effect of Nintedanib in a rat model of lung fibrosis induced by single or double bleomycin administration Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis Source: Eur Respir J 2006; 27: 460-469 Year: 2006 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 PBI-compound, a novel first-in-class anti-fibrotic compound, inhibits CTGF and collagen production in murine and human fibroblasts, and reduces lung fibrosis in the bleomycin-induced lung fibrosis model Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats Source: Eur Respir J 2001; 17: 1228-1235 Year: 2001 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Correlation of Nintedanib efficacy on fibrotic lesion deposition and lung function within a rat IPF model Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice Source: Eur Respir J 2005; 25: 708-714 Year: 2005 Interferon-γ pretreated human MSC show improved efficiency in humanized mice model of pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Bleomycin induced lung fibrosis in mice is attenuated by a new somatostatin analog Source: Annual Congress 2006 - Matrix remodelling at the interface of lung fibrosis and emphysema Year: 2006